Unique, dedicated global capabilities support our strategy
Our Global Capabilities
Worldwide commercial and development organization in more than 85 countries, with more than a decade of experience and over 10,000 employees dedicated to oncology research and development.
Unmatched portfolio of 22 oncology, hematology and rare disease medicines to treat more than 25 conditions worldwide.
Internal capabilities dedicated to developing companion diagnostics that help physicians make the best treatment decisions for their patients.
Precision oncology accelerates development and improves results
At Novartis Oncology, we are a leader in driving the practice of precision oncology treatment. Precision oncology is the evolving understanding of how cancers develop on a genomic level and our ability to develop drugs that hone in on those targets – ultimately leading to better patient outcomes.
Our research is driven by a distinctive scientific and clinical strategy, focusing on unmet medical needs and disease pathways:
Identify pathways most commonly associated with cancer
Screen compounds to identify ones with greatest potential to impact pathway
Identify biomarkers and create diagnostic tools
Target patients most likely to benefit from therapy
Thanks to this approach, the Novartis Oncology Pipeline is one of the strongest and most productive pipelines in the industry. The recent acquisition of the GSK oncology portfolio strengthens our industry-leading pipeline in precision cancer treatment and brings exciting potential to the development of combination regimens.
Together, we discover innovative medicines that help improve the lives of cancer patients.
Patient-inspired solutions provide more than medicine
Treating cancer and related diseases is about supporting patients with more than medicine:
Disease-specific programs provide comprehensive support to patients, helping to ensure the best outcome in collaboration with providers and payers.
Our innovative portfolio of access-to-treatment projects adapts to patient needs, products, partners and countries.
Connecting with patient groups and others in the community helps us understand and reflect patient needs. Working together, we have established a variety of disease alliances aimed at supporting the varied needs of all those involved in the drug treatment process. Our track record of innovative access programs is unmatched in the industry. With the addition of the GSK oncology product portfolio, we will develop new connections and leverage existing relationships to improve outcomes and the availability of medicines.